Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study

Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study

Abstract Background This Phase 3, open-label, rollover study (NCT01323244) investigated the efficacy and safety of simeprevir plus peginterferon α-2a (PegIFNα-2a) and ribavirin (RBV) in a well-characterized population of HCV genotype 1 (GT1)-infected treatment-experienced patients. Methods Patients...

Full description

Bibliographic Details
Main Authors: Edward J. Gane, Edwin DeJesus, Ewa Janczewska, Jacob George, Moises Diago, Mariliza Hendrique Da Silva, Henk Reesink, Igor Nikitin, Holger Hinrichsen, Stefan Bourgeois, Peter Ferenci, Umesh Shukla, Ronald Kalmeijer, Oliver Lenz, Bart Fevery, Chris Corbett, Maria Beumont, Wolfgang Jessner
Format: Article
Language:English
Published: BMC 2017-06-01
Series:BMC Infectious Diseases
Subjects:
Chronic hepatitis C
Direct-acting antiviral therapy
Peginterferon
Ribavirin
Safety
Simeprevir
Online Access:http://link.springer.com/article/10.1186/s12879-017-2444-3

Internet

http://link.springer.com/article/10.1186/s12879-017-2444-3

Similar Items